New clinical data shows that oxidized cholesterol is removed from the body for the first time.
Heart disease is like a leak in the ceiling where you do damage control, slow the spread, hope it’s contained. However, new clinical data suggests that medicine may finally be able to step up to something more ambitious and actually clean up some of its own damage.
In Scientific Sessions of the American Heart Association Vascular Discovery in Washington, D.C., Clinical Stage Biotechnology Periodic therapy What it says is the first human evidence to show the safe excretion of 7-ketocholesterol (7KC), a toxic form of oxidized cholesterol that is strongly associated with the formation of arterial plaque (1).
For a field that for decades has focused primarily on risk reduction, the findings are significant not because they promise a cure (they don’t), but because they point to a different philosophy of treatment.
Modern cardiovascular medicine has been remarkably successful in saving lives. Statins lower cholesterol. Anti-inflammatory drugs reduce cardiovascular risk. New therapies based on RNA have helped to understand how the body regulates the fats and proteins that are linked to the disease. But even the best treatments usually work by slowing the progression rather than reversing the biological wear and tear that has already built up inside the arteries.
Atherosclerotic plaque is not just excess cholesterol floating around in the bloodstream. Over time, some of the cholesterol is oxidized – chemically changed, making it toxic to the surrounding tissue. One of the harmful forms is 7KC, which accumulates within plaques and contributes to inflammation, cell death, and blood vessel instability.
You can think of it as corrosive sludge hardening on the walls. Cyclarity’s experimental therapy, UDP-003, is specifically designed to target this sludge.
Dr Stephen Nicholls, director of the Monash Heart Institute Victoria and lead investigator of the trial, said: “Cardiovascular disease remains the leading cause of death in the world, but most treatments are aimed at slowing its progression rather than reversing the underlying damage that drives it.”
Nichols said preliminary data from the UDP-003 clinical trial suggest a fundamental change in the way cardiovascular disease is treated. He noted that the test provides the first evidence of the release of oxidized cholesterol in humans, suggesting that while these results are an early step, they indicate the potential to reverse atherosclerosis.
Furthermore, Nicholls emphasized that this development could ultimately protect patients by preventing the initial accumulation of oxidized cholesterol. The basic idea of the treatment is amazing.
UDP-003 belongs to a class of molecules called cyclodextrins, ring-shaped compounds that can bind to certain substances almost like small molecular cages. Cyclarity designed its version to specifically bind to 7KC, making the toxic material water-soluble so the body can excrete it through urine.
In other words, instead of changing cholesterol production throughout the body, the therapy aims to physically capture and remove the harmful product directly from the plaque itself.
The company describes it as eliminating rust, not just slowing down corrosion. This distinction may ultimately be important for longevity science, which is increasingly moving away from managing symptoms and toward addressing cumulative biological damage. Gerontology researchers have debated for years whether age-related diseases can really be changed at their root rather than being managed at the bottom of an endless stream. Findings like these — however early — add fuel to the conversation.
Cardiovascular health is at the center of almost every longevity discussion for a reason. Aging arteries affect more than the heart. Decreased vascular function affects the brain, kidneys, muscles, and metabolism, which accelerates deterioration throughout the body. This systemic effect is part of what makes 7KC interesting beyond cardiology.
Researchers have also linked oxidized cholesterol to conditions including Alzheimer’s disease and metabolic disorders such as NASH, although it is unclear how directly targeting it might affect these diseases.
“Maintaining cardiovascular health is one of the most powerful levers for extending both life and health, given its central role in slowing systemic aging and maintaining brain, kidney, muscle and metabolic function,” said Cyclarity Co-CEO and founder Dr. Matthew O’Connor.
O’Connor expressed optimism about the future of his research after showing that their approach can accurately bind to and safely remove toxic products without interfering with vital biological systems. He noted that the team looks forward to their work to develop treatments that could save millions of lives and fundamentally change the current trajectory of the aging process.
There is also a significant cultural thing going on here. Long-term biotechnology is often criticized for chasing abstractions (say, biomarkers, clocks, optimization metrics) and providing limited evidence that aging-related damage can be reversed in humans.
Periodic data, while preliminary, has more of a feel. The company doesn’t just measure risk factors or predict healthy aging decades ahead. It tries to remove a harmful substance that is already inside the body.
The trial itself was a phase 1 study designed primarily to assess safety. Participants received UDP-003 or placebo at several dose levels, including a group with a history of major cardiac events.
According to the company, no serious adverse events were observed. The researchers also reported that urinary excretion of 7KC was dose-dependent, meaning that the more treatment participants took, the more oxidized cholesterol left the body.
Yes, incremental, but in cardiovascular medicine, incremental changes can be very important. Research has shown that even a 1% reduction in coronary plaque burden can significantly reduce the risk of major cardiovascular events.
Cyclarity is now enrolling patients in the next phase of the trial, which will use coronary imaging to determine whether the plaque itself shrinks measurably after treatment. A phase 2 study is expected later this year.
In the meantime, caution is warranted. Many treatments show promise before being tested in large studies. No one yet knows if clearing 7KC translates into fewer heart attacks, longer life, or slower biological aging. However, the idea itself is new in an industry that often accepts a slow decline as the best-case scenario.
